In patients with familial hypercholesterolemia without cardiovascular disease, PCSK9 inhibitors can be considered if LDLc is higher than 200 mg/dL, or even lower, 175 mg/dL, if there are additional severity factors [27]. The gene discussed is PCSK9; the disease is familial hypercholesterolemia.